Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows a mixed picture: revenue increased by 25% YoY, but the company still reported a net loss. Operating expenses rose due to R&D and sales expansion, indicating a focus on growth. The cash position is strong, despite a slight decrease. However, the lack of discussion on strategic initiatives and unclear management responses in the Q&A introduce uncertainty. Overall, the financial improvements are tempered by risks and uncertainties, suggesting a neutral sentiment over the next two weeks.
Key Financial Performance
Revenue Nautilus Biotechnology reported revenue of $15 million for Q1 2026, representing a 25% increase year-over-year. This growth was attributed to increased adoption of their proteomics platform and expansion into new markets.
Net Loss The company reported a net loss of $10 million for Q1 2026, which is an improvement from the $12 million net loss in Q1 2025. The reduction in net loss was due to cost optimization measures and increased revenue.
Operating Expenses Operating expenses were $20 million for Q1 2026, up 10% year-over-year. The increase was driven by higher R&D investments and expansion of the sales team.
Cash and Cash Equivalents Nautilus ended Q1 2026 with $120 million in cash and cash equivalents, down from $130 million at the end of Q1 2025. The decrease was primarily due to ongoing investments in product development and market expansion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: Management will make statements that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anna Mowry
Biotechnology Conference
Boucher TD
CEO President
CFO Treasurer
Chief Scientist
Co Founder
Cowen Research
Director Anna
Director Parag
Division EDT
Division Kyle
EDT day
Founder CEO
Founder Chief
Guggenheim Securities
Kyle Boucher
LLC Research
Mallick Co
Mowry CFO
Nambi Guggenheim
Parag Mallick
Patel Co
President Secretary
Research Division
Scientist Director
Securities LLC
Subhalaxmi Nambi
Treasurer Subhalaxmi
NAUT Transcript
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Unknown4-28
The earnings call shows a mixed picture: revenue increased by 25% YoY, but the company still reported a net loss. Operating expenses rose due to R&D and sales expansion, indicating a focus on growth. The cash position is strong, despite a slight decrease. However, the lack of discussion on strategic initiatives and unclear management responses in the Q&A introduce uncertainty. Overall, the financial improvements are tempered by risks and uncertainties, suggesting a neutral sentiment over the next two weeks.
Nautilus Biotechnology, Inc. (NAUT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-6
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed outlook. While there is excitement about the Early Access Program and a decrease in operating expenses, there are significant risks, including regulatory challenges, financial sustainability concerns, and competitive pressures. The limited near-term revenue and lack of updates on key financial metrics like pricing also contribute to the neutral sentiment. The positive feedback from early customers is offset by the uncertainty in revenue generation and market entry, leading to a balanced view with no strong catalysts for short-term stock movement.
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call summary presents a mixed picture. Financial performance shows cost reductions and a strong cash position, but with limited near-term revenue. Product development is progressing, yet commercialization faces risks. Market strategy is promising with strong customer interest, but adoption risks exist. Expenses are well-managed, but increased spending is expected. Q&A insights reveal cautious optimism but lack specific guidance. Overall, the lack of immediate revenue and commercialization challenges balance the positives, leading to a neutral sentiment.
NAUT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
